SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as investors react to escalating US-China trade tensions and await insights from upcoming bank earnings and a speech from Fed Chair Powell. Community chatter reflects concerns about market volatility, potential pullbacks, and the impact of Trump's trade policies. Some traders are anticipating a buying opportunity amidst the uncertainty, while others are bracing for a deeper correction.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid discussions about market manipulation and potential trade war impacts, with community members debating whether recent price dips represent buying opportunities or signs of a larger correction. Concerns about leveraged positions and insider activity are also circulating, while some analysts maintain a bullish long-term outlook. The digital asset's performance is being closely watched in relation to traditional markets and geopolitical developments.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to renewed US-China trade war concerns sparked by China's sanctions on a Korean shipbuilder and the potential for further tariff escalations, creating market volatility. Community discussions revolve around whether these movements are news-driven rather than technical, and whether Trump's actions will reverse the current downturn. Overall sentiment seems mixed, with some expecting a bounce while others anticipate further drawdowns.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst ($BCRX) is trending amid news of its acquisition of Astria Therapeutics ($ATXS) to bolster its HAE portfolio, a move that has sparked mixed reactions. While some investors see long-term growth potential, others express concerns about the acquisition's cost and potential impact on profitability, leading to active discussions about the company's future direction and valuation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

$CRML is trending as the U.S. aims to secure rare earth elements and reduce reliance on China, sparking community interest in resource independence and potential government support. Discussions revolve around the company's assets in Greenland and the potential for significant growth in a sector deemed critical for national security. Some traders are pointing to a large move in a related ticker, $CLIK, as a reason for caution.

Nova Minerals Ltd. engages in the exploration and development of mineral properties. Its projects include Estelle Gold, RPM, Korbel, Train, Stoney and Studies projects. The company was founded in January 1987 and is headquartered in Melbourne, Australia.

Nova Minerals Limited - ADR

Nova Minerals is trending as discussions revolve around its potential to become a key domestic antimony supplier, especially after the U.S. Department of War awarded funds to Alaska Range Resources (ARR), its subsidiary, to secure the antimony supply chain. The community is focused on the company's unique position with both antimony and gold prospects, viewing it as undervalued compared to other rare earth plays. Some investors express enthusiasm about NVA's long-term growth potential given its Alaskan mining assets.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

GWAV is trending due to discussions around potential short squeezes and high volatility, with traders actively speculating on entry and exit points. Community members are weighing in on the stock's potential for a significant run-up, while others highlight concerns about past dilutions and reverse splits. The stock's low float and presence in the recycling and critical metals space are also contributing to the heightened interest.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending due to progress in developing GaN and SiC power devices for NVIDIA's next-gen AI factory architecture, specifically supporting the 800 VDC power architecture. The community is focused on the potential for increased efficiency and power density in AI data centers, with some speculating about a possible short squeeze given the stock's high short interest. Some traders are drawing parallels to other AI-related stocks and anticipating further upside.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending following the release of its Q3 2025 earnings, which revealed profits boosted by investment banking and trading. Community members are actively discussing the better-than-expected revenue and trading results, while also pointing out a net reserve build. Some are speculating on the potential impact of the earnings on the broader market.

PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed, Braeden William Lichti, and Jordan R. Plews on June 9, 2020 and is headquartered in Newport Beach, CA.

PMGC Holdings Inc

PMGC Holdings Inc.

ELAB is trending due to a premarket surge, fueled by retail trader interest in PMGC Holdings' shift towards biotech and industrial sectors. Community discussions revolve around the stock's low float and potential for a squeeze, while some traders are pointing to possible overextension. The stock's volatility and previous reverse splits are also being discussed.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celcuity Inc. (CELC) stock surged about 221% on Monday morning after the company announced that its experimental combination treatment demonstrated a reduction in the risk of disease progression or death in patients with a type of advanced breast cancer in a late-stage study.The firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.celcuity.com/press-releases/">said</a> that the combination of Gedatolisib, Fulvestrant, and Palbociclib reduced the risk of disease progression or death by 76% compared to Fulvestrant alone in patients with previously treated HR+/HER2- advanced breast cancer.Median progression-free survival was 9.3 months with the Gedatolisib triplet compared to two months with Fulvestrant alone, meaning patients lived an average of 9.3 months without progression of disease with the treatment.A combination of Gedatolisib plus Fulvestrant reduced the risk of disease progression or death by 67% compared to Fulvestrant, with a median progression-free survival of 7.4 months.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CELC">Celcuity</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_28_at_9_01_25_AM_png_aec1ab2846.webp" alt="CELC's Sentiment Meter and Message Volume as of 9 a.m. ET on July 28, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>CELC's Sentiment Meter and Message Volume as of 9 a.m. ET on July 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that they expect a peak market valuation of three to five billion dollars for the company.<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/622681433</stembedurl>Another said that the news is worth at least a 500% rally.<stembedurl>https://stocktwits.com/madape/message/622680399</stembedurl> Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide. According to Celcuity, HR+/HER2- breast cancer is the most common subtype of breast cancer, accounting for approximately 70% of all breast cancers.The improvements in progression-free survival observed in the study with the combinations were statistically significant and clinically meaningful, the company said.Both the combinations were better tolerated than observed in an early-stage trial in patients with advanced breast cancer, it added.Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”“The efficacy improvement relative to the control that each of the gedatolisib regimens demonstrated was historic for this patient population,” CEO Brian Sullivan added.Celcuity expects to submit a new drug application for Gedatolisib to the U.S. Food and Drug Administration in the fourth quarter of 2025.CELC stock is up by about 238% this year and by 147% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/weride-receives-autnomous-driving-permit-in-saudi-arabia/choeFojR5Dy">WeRide Receives Autonomous Driving Permit in Saudi Arabia: Retail Sees Stock Hitting $20</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why

Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”

Equity

Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”


Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 PR Newswire VANCOUVER...

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...

Celcuity Inc.'s (NASDAQ:CELC) large institutional owners must be happy as stock continues to impress, up 12% over the past week

Key Insights Institutions' substantial holdings in Celcuity implies that they have significant influence over the...

Celcuity (NASDAQ:CELC) Price Target Increased to $24.00 by Analysts at Needham & Company LLC

Celcuity (NASDAQ:CELC - Free Report) had its price target hoisted by Needham  Company LLC from $23.00 to $24.00 in a research report released on Thursday, Benzinga reports. Needham  Company...

Celcuity (NASDAQ:CELC - Get Free Report) had its price objective increased by equities researchers at Needham & Company LLC from $23.00 to $24.00 in a research report issued to clients and investors...

Celcuity (NASDAQ:CELC) Given New $25.00 Price Target at Craig Hallum

Celcuity (NASDAQ:CELC  Free Report) had its target price lifted by Craig Hallum from $20.00 to $25.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has a buy...

Celcuity Inc.'s Balancing Act: Navigating Financial Risks in Capital Raising Endeavors

Celcuity Inc. (CELC) has disclosed a new risk, in the Share Price & Shareholder Rights category. Celcuity Inc. faces significant financial risks as...

Celcuity (CELC, $21.58) RSI Indicator left the overbought zone on March 28, 2024

This is a signal that CELC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Celcuity (CELC, $21.58) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 28, 2024

This is a Bullish indicator signaling CELC's price could rise from here. Traders may explore going long the stock or buying call options...

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.02	--	--	N/A
Q2 '25	-$0.88	-$1.04	-17.61%	MISSED
Q1 '25	-$0.86	-$0.86	0.19%	BEAT
Q4 '24	-$0.71	-$0.85	-19.96%	MISSED
Q3 '24	-$0.65	-$0.70	-7.22%	MISSED

CELC
Celcuity Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest CELC News

CELCCelcuity Inc